Medical Crossfire: A Payer and Neurologist Discussion on the Shifting Paradigm of Alzheimer

https://www.pharmacytimes.org/on-demand/an-american-journal-of-managed-care-medical-crossfire-a-payer-and-neurologist-discussion-on-the-shifting-paradigm-of-alzheimers-disease-treatment

Related Videos

Related Content

Advertisement

April 3rd 2025

Dr Oz Confirmed by the Senate Along Party Lines to Lead CMS

Laura Joszt, MA

The former television personality and heart surgeon was confirmed in a 53-45 vote on party lines.

February 25th 2025

Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care

Pearl Steinzor Arthur L. Jenkins III, MD, FACS

On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.

April 3rd 2025

11% of Americans Cannot Access Quality Health Care, Survey Finds

Julia Bonavitacola

The West Health-Gallup Healthcare Indices Study indicates that approximately 29 million people are unable to afford or access quality healthcare, the highest since 2021.

February 18th 2025

Varied Access: The Pharmacogenetic Testing Coverage Divide

Brooke McCormick Jai N. Patel, PharmD

On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.

April 3rd 2025

Radiation Bridging Therapy Boosts CAR T Outcomes in R/R LBCL

Maggie L. Shaw

In this comparative analysis, patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) received bridging therapy via radiation or systemic treatment while their chimeric antigen receptor T-cell therapy (CAR T) was being manufactured.

April 3rd 2025

Combined Effect of Continuous Glucose Monitoring and Semaglutide: Analysis of Administrative Claims

Poorva M. Nemlekar, MS Katia L. Hannah, PhD, MPH Courtney R. Green, PhD Thomas Grace, MD Peter M. Lynch, MPH Jessica R. Castle, MD Gregory J. Norman, PhD

Claims data reveal larger hemoglobin A1c decreases in people with type 2 diabetes who use continuous glucose monitoring and semaglutide compared with semaglutide alone.

Related Content

Advertisement

April 3rd 2025

Dr Oz Confirmed by the Senate Along Party Lines to Lead CMS

Laura Joszt, MA

The former television personality and heart surgeon was confirmed in a 53-45 vote on party lines.

February 25th 2025

Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care

Pearl Steinzor Arthur L. Jenkins III, MD, FACS

On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.

April 3rd 2025

11% of Americans Cannot Access Quality Health Care, Survey Finds

Julia Bonavitacola

The West Health-Gallup Healthcare Indices Study indicates that approximately 29 million people are unable to afford or access quality healthcare, the highest since 2021.

February 18th 2025

Varied Access: The Pharmacogenetic Testing Coverage Divide

Brooke McCormick Jai N. Patel, PharmD

On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.

April 3rd 2025

Radiation Bridging Therapy Boosts CAR T Outcomes in R/R LBCL

Maggie L. Shaw

In this comparative analysis, patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) received bridging therapy via radiation or systemic treatment while their chimeric antigen receptor T-cell therapy (CAR T) was being manufactured.

April 3rd 2025

Combined Effect of Continuous Glucose Monitoring and Semaglutide: Analysis of Administrative Claims

Poorva M. Nemlekar, MS Katia L. Hannah, PhD, MPH Courtney R. Green, PhD Thomas Grace, MD Peter M. Lynch, MPH Jessica R. Castle, MD Gregory J. Norman, PhD

Claims data reveal larger hemoglobin A1c decreases in people with type 2 diabetes who use continuous glucose monitoring and semaglutide compared with semaglutide alone.